Terms: = Colorectal cancer AND ATF1, TREB36, 466, ENSG00000123268, P18846 AND Prognosis
23 results:
1. Metastatic pattern is a prognostic factor in BRAF
Ji J; Sandhu J; Wang C; Fakih M
Cancer Treat Res Commun; 2023; 35():100714. PubMed ID: 37126990
[TBL] [Abstract] [Full Text] [Related]
2. Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study.
Sanjinez C; Botteri E; Støer NC; Lukas Löfling L
Lung Cancer; 2023 May; 179():107187. PubMed ID: 37060880
[TBL] [Abstract] [Full Text] [Related]
3. Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.
Corry SM; McCorry AM; Lannagan TR; Leonard NA; Fisher NC; Byrne RM; Tsantoulis P; Cortes-Lavaud X; Amirkhah R; Redmond KL; McCooey AJ; Malla SB; Rogan E; Sakhnevych S; Gillespie MA; White M; Richman SD; Jackstadt RF; Campbell AD; Maguire S; ; McDade SS; Longley DB; Loughrey MB; Coleman HG; Kerr EM; Tejpar S; Maughan T; Leedham SJ; Small DM; Ryan AE; Sansom OJ; Lawler M; Dunne PD
Gut; 2022 Dec; 71(12):2502-2517. PubMed ID: 35477539
[TBL] [Abstract] [Full Text] [Related]
4. Parenchyma-sparing strategy and oncological prognosis in patients with colorectal cancer liver metastases.
Burlaka AA; Makhmudov DE; Lisnyi II; Paliichuk AV; Zvirych VV; Lukashenko AV
World J Surg Oncol; 2022 Apr; 20(1):122. PubMed ID: 35430799
[TBL] [Abstract] [Full Text] [Related]
5. Real-World Outcomes of Patients With BRAF-Mutated Metastatic colorectal cancer Treated in the United States.
Trunk A; Braithwaite M; Nevala-Plagemann C; Pappas L; Haaland B; Garrido-Laguna I
J Natl Compr Canc Netw; 2022 Feb; 20(2):144-150. PubMed ID: 35130499
[TBL] [Abstract] [Full Text] [Related]
6. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
7. MiR-466 as a poor prognostic predictor suppresses cell proliferation and EMT in breast cancer cells by targeting PSMA7.
Xiao Y; Zhang SJ; Yan X; Wu C; Liu QW; Dong HX; Wang LJ; Hu Y
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5625-5635. PubMed ID: 34604955
[TBL] [Abstract] [Full Text] [Related]
8. [Comparison of the mid- and long-term outcomes between natural orifice specimen extraction surgery and conventional laparoscopic surgery with abdominal auxiliary incision in the treatment of rectal cancer based on propensity score matching method].
Xu S; Zhang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Aug; 24(8):698-703. PubMed ID: 34412187
[No Abstract] [Full Text] [Related]
9. Care Patterns and Overall Survival in Patients With Early-Onset Metastatic colorectal cancer.
Kanter K; Fish M; Mauri G; Horick NK; Allen JN; Blaszkowsky LS; Clark JW; Ryan DP; Nipp RD; Giantonio BJ; Goyal L; Dubois J; Murphy JE; Franses J; Klempner SJ; Roeland EJ; Weekes CD; Wo JY; Hong TS; Van Seventer EE; Corcoran RB; Parikh AR
JCO Oncol Pract; 2021 Dec; 17(12):e1846-e1855. PubMed ID: 34043449
[TBL] [Abstract] [Full Text] [Related]
10. Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Catalano V; Bergamo F; Cremolini C; Vincenzi B; Negri F; Giordani P; Alessandroni P; Intini R; Stragliotto S; Rossini D; Borelli B; Santini D; Sarti D; Rocchi MBL; Lonardi S; Falcone A; Zagonel V; Mattioli R; Graziano F
J Cancer Res Clin Oncol; 2020 Feb; 146(2):493-501. PubMed ID: 31691872
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer.
Colloca GA; Venturino A; Guarneri D
Int J Clin Oncol; 2019 Nov; 24(11):1406-1411. PubMed ID: 31289956
[TBL] [Abstract] [Full Text] [Related]
12. Overexpression of G protein-coupled receptor 31 as a poor prognosticator in human colorectal cancer.
Rong YM; Huang XM; Fan DJ; Lin XT; Zhang F; Hu JC; Tan YX; Chen X; Zou YF; Lan P
World J Gastroenterol; 2018 Nov; 24(41):4679-4690. PubMed ID: 30416315
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of three classifications for lymph node evaluation in patients undergoing total mesorectal excision for rectal cancer.
Fritzmann J; Contin P; Reissfelder C; Büchler MW; Weitz J; Rahbari NN; Ulrich AB
Langenbecks Arch Surg; 2018 Jun; 403(4):451-462. PubMed ID: 29523953
[TBL] [Abstract] [Full Text] [Related]
14. MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC).
Tong F; Ying Y; Pan H; Zhao W; Li H; Zhan X
Bosn J Basic Med Sci; 2018 Aug; 18(3):252-259. PubMed ID: 29338680
[TBL] [Abstract] [Full Text] [Related]
15. Disentangling the prognostic heterogeneity of stage III colorectal cancer through histologic stromal categorization.
Ueno H; Sekine S; Oshiro T; Kanemitsu Y; Hamaguchi T; Shida D; Takashima A; Ishiguro M; Ito E; Hashiguchi Y; Kondo F; Shimazaki H; Mochizuki S; Kajiwara Y; Shinto E; Yamamoto J; Shimada Y
Surgery; 2018 Apr; 163(4):777-783. PubMed ID: 29162344
[TBL] [Abstract] [Full Text] [Related]
16. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Buettner S; Amini N; Pawlik TM
J Surg Oncol; 2016 Sep; 114(3):361-7. PubMed ID: 27264476
[TBL] [Abstract] [Full Text] [Related]
17. Significance of R1 Resection for Advanced colorectal Liver Metastases in the Era of Modern Effective Chemotherapy.
Laurent C; Adam JP; Denost Q; Smith D; Saric J; Chiche L
World J Surg; 2016 May; 40(5):1191-9. PubMed ID: 26757718
[TBL] [Abstract] [Full Text] [Related]
18. [Prognostic analysis of different treatments for synchronous colorectal liver metastasis].
Tian Y; Xu X; Gao H; Wang L; Gao Z; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Nov; 18(11):1115-8. PubMed ID: 26616805
[TBL] [Abstract] [Full Text] [Related]
19. Large differences in global transcriptional regulatory programs of normal and tumor colon cells.
Cordero D; Solé X; Crous-Bou M; Sanz-Pamplona R; Paré-Brunet L; Guinó E; Olivares D; Berenguer A; Santos C; Salazar R; Biondo S; Moreno V
BMC Cancer; 2014 Sep; 14():708. PubMed ID: 25253512
[TBL] [Abstract] [Full Text] [Related]
20. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies.
Wang ZH; Gao QY; Fang JY
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1647-55. PubMed ID: 22610356
[TBL] [Abstract] [Full Text] [Related]
[Next]
